Made possible by a charitable contribution from Bayer
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.

Greetings!

We hope that you’re doing well and off to a great start in the new year! We’re pleased to provide you with some of the latest Prostate Cancer News You Can Use along with the information below that may be of interest to you. Titles of prostate cancer news articles are also listed with a link to the Us TOO web page that provides access to the full text for each article.

We’d like to thank everyone who donated to the Us TOO Holiday Hope fundraising campaign. Funds will be used to help support the work that we do at Us TOO providing educational resources, support services and personal connections to the prostate cancer community at no charge. 
 
If you haven’t yet done so, we encourage you to check out the video from the Us TOO Prostate Cancer Pathways event and webcast presented in Chicago on November 9. Prostate cancer medical experts covered various topics identified as being most important to men with prostate cancer, based on recent survey responses from Us TOO support group leaders. Presentations and panel discussions featured: Nelson Bennett, Jr., MD; Maha Hussain, MD, FACP, FASCO; Shilajit D. Kundu, MD; Alicia Morgans, MD, MPH; Sean Sachdev, MD; David J. VanderWeele, MD, PhD; Genetic Counselor Carmen Williams. Topics that were addressed included Active Surveillance, Surgical Options & Side Effects, Prostate Cancer Radiotherapy, Prostate Cancer & the Penis, Prostate Cancer Patient Perspective, Genetics & Prostate Cancer, Advanced Prostate Cancer, Genomic/Molecular Testing & Bone Strength. Video content is labeled by specific topics for each segment for quick and easy access to brief segments or the entire webcast.

NEWS YOU CAN USE ARTICLES:
Please note that the content below lists only the title of the article rather than a direct link to the content. For access to the full article  CLICK HERE .

  • Researchers from University of Texas M.D. Anderson Cancer Center Report Details of New Studies and Findings in the Area of Prostate Cancer (Novel Method To Detect, Isolate, and Culture Prostate Culturing Circulating Tumor Cells)
  • Targeted screening could prevent one in six prostate cancer deaths
  • Clovis Oncology’s Rubraca® rucaparib Granted FDA Priority Review for Advanced Prostate Cancer
  • Data on Prostate Cancer Described by Researchers at University Hospital (A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy)
  • National veteran dataset will help dissect mental illness, prostate cancer connections
  • Investigators at University of South Alabama Zero in on Prostate Cancer (Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope)
  • AI can be used to detect and grade prostate cancer
  • Eating fruit, vegetables won't slow prostate cancer, study finds
  • Research Results from Geneva University Hospitals Update Understanding of Prostate Cancer (Prostate Cancer Nonascitic Peritoneal Carcinomatosis After Robot-assisted Laparoscopic Radical Prostatectomy: 3 Case Reports and Review of the Literature)
  • Findings from Hannover Medical School Broadens Understanding of Prostate Cancer (18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging)
  • Researchers from Griffith University Report Details of New Studies and Findings in the Area of Prostate Cancer (Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review)
  • Data on Prostate Cancer Reported by Researchers at Peter MacCallum Cancer Center (Navigating Systemic Therapy for Metastatic Castration-naive Prostate Cancer)


MORE NEWS:
CLINICAL TRIAL - The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer. Get More Information or Details on ClinicalTrials.gov

CLINICAL TRIAL - Janssen Research & Development is seeking men in the US to participate in a clinical trial of an oral investigational medication for prostate cancer. All participants will receive daily investigational medication. To learn more about the Galahad study and find out if you may be eligible, get Details on ClinicalTrials.gov. (Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson).

Watch for the February 2020 issue of the Us TOO Hot SHEET newsletter, and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.

Finally, let me introduce myself. My name is Beau Stubblefield-Tave, and I became Executive Director of Us TOO, International in January, 2020. In January, 2011, I had a successful radical prostatectomy and joined the community of prostate cancer survivors. I am honored to bring my experience as a survivor, health services executive, and diversity, equity, and inclusion consultant to the Us TOO team. For more information, please visit https://conta.cc/2Rf41m3.


Shalom. Salaam. Peace.

Beau Stubblefield-Tave and the Us TOO Team
Beau Stubblefield-Tave , Executive Director
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Director